EPO and myelodysplastic syndrome: [177] reported that S100A9 directly inhibits the elaboration of erythropoietin and the endocrine response to anemia, while neutralization or suppression of S100A9 could reverse the processes and thus erythropoiesis enhancement in patients with low-risk MDS (LR-MDS).